John Newman
Stock Analyst at Canaccord Genuity
(2.18)
# 2,854
Out of 5,044 analysts
84
Total ratings
46.58%
Success rate
-5.06%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 | $654.48 | +29.87% | 19 | Oct 23, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $10.15 | +106.90% | 2 | Oct 21, 2025 | |
| MRUS Merus | Downgrades: Hold | $67 → $97 | $94.89 | +2.22% | 3 | Sep 30, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $17.16 | +28.21% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.26 | +1,011.11% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $105.03 | +63.23% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $15.21 | +11.77% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.01 | +692.08% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $5.60 | +346.43% | 2 | Feb 26, 2025 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $87.49 | +31.44% | 8 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $8 | $0.86 | +835.02% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $8.32 | +416.83% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.22 | +309.84% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $43.43 | +1.31% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $14.67 | +159.03% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.14 | +425.29% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $12.63 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Oct 23, 2025
Maintains: Buy
Price Target: $850
Current: $654.48
Upside: +29.87%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $10.15
Upside: +106.90%
Merus
Sep 30, 2025
Downgrades: Hold
Price Target: $67 → $97
Current: $94.89
Upside: +2.22%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $17.16
Upside: +28.21%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.26
Upside: +1,011.11%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $105.03
Upside: +63.23%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $15.21
Upside: +11.77%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.01
Upside: +692.08%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.60
Upside: +346.43%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $87.49
Upside: +31.44%
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.86
Upside: +835.02%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $8.32
Upside: +416.83%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.22
Upside: +309.84%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $43.43
Upside: +1.31%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $14.67
Upside: +159.03%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.14
Upside: +425.29%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $12.63
Upside: -